GSK at SRD5A2
As of the edition of 20 October 2026, GSK is on route B at SRD5A2 (3-oxo-5-alpha-steroid 4-dehydrogenase 2), position 6 of 2,016 on that route, with a score of 0.794.
Sources: ClinicalTrials.gov, approval registers, ChEMBL, FDA Orange Book and Purple Book.
Route and score
Route B Score 0.794
Biology proven in humans0.90
How much the company cares0.88
Room, and a reason to act now0.63
Each part runs from 0 to 1; 0.5 is neutral, and an unknown fact counts as neutral.
What moved the score
Proof in humans at the target+0.294
Took its own drug far in human testing+0.225
Active at the target or its disease area recently+0.159
Trials at the target more often meet than miss their main endpoint+0.103
Few other companies active at the target+0.087
The company’s own follow-on drug+0.044
Why its own drug stopped0.000
The facts that decided the route
- Does the company have its own row at this target, rather than being counted under a drug that acts on many targets? The company has its own row at this target As of 20 October 2026.
- Has the company not been dissolved without a successor? The company still exists or has a successor As of 19 March 2008.
- Does the company have a marketed drug at this target? The company has a marketed drug at this target As of 20 November 2001.
- Does the company have no approved follow-on drug at this target? The company has no approved follow-on of its own As of 20 November 2001.
- Is the protein the drug acts on identified, and not only a complex it belongs to? The protein the drug acts on is on record, not only its complex As of 20 October 2026.
- Does a source say which of the drug's many targets it is designed for? The target the drug is designed for is established As of 20 October 2026.
The drugs
| Drug | Status | Furthest phase | Trials | US protection |
|---|---|---|---|---|
| Dutasteride | Marketed | Phase 4 | 82 | none listed |
The trials behind it
| Trial | Drug | Phase | Status | Years | Participants | Result |
|---|---|---|---|---|---|---|
| NCT01673490 | Dutasteride | Phase 4 | Terminated | 2012 to 2015 | 59 | Result could not be read |
| The registry records: “The sole investigative site refused to accept the amended protocol and declined to continue the study. There was no safety signal nor any other reason.” | ||||||
| NCT00421421 | Dutasteride | Phase 4 | Terminated | 2007 | 276 | No results posted |
| The registry records: “Incomplete information” | ||||||
| NCT02509104 | Dutasteride | Phase 1 | Completed | 2015 to 2015 | 56 | No results posted |
| NCT02014584 | Dutasteride | Phase 3 | Completed | 2014 to 2016 | 117 | Main endpoint missed |
| NCT02058368 | Dutasteride | Phase 3 | Completed | 2014 to 2017 | 607 | Mixed result |
| NCT01957189 | Dutasteride | Phase 1 | Completed | 2013 to 2014 | 24 | No results posted |
| NCT01929330 | Dutasteride | Phase 1 | Completed | 2013 to 2014 | 36 | No results posted |
| NCT01831791 | Dutasteride | Phase 3 | Completed | 2013 to 2014 | 120 | No results posted |
| NCT01777269 | Dutasteride | Phase 4 | Completed | 2013 to 2016 | 489 | Main endpoint met |
| NCT01657851 | Dutasteride | Phase 1 | Completed | 2012 to 2012 | 35 | No results posted |
| NCT01495026 | Dutasteride | Phase 1 | Completed | 2011 to 2012 | 63 | No results posted |
| NCT01471678 | Dutasteride | Phase 1 | Completed | 2011 to 2011 | 27 | No results posted |